Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most safety-related interaction statements about grapefruit juice increasing atorvastatin plasma concentrations via CYP3A4 inhibition are supported by the provided label excerpts. However, multiple claims are not fully supported (e.g., blanket 'avoid all citrus juice', specific timing 'within 30 minutes to 1 hour', inclusion of kidney damage/renal failure, and CYP3A4 'breaking down in the liver' phrasing), and some interaction scope statements (other medication classes) are not supported in the provided label text.
Category Scores
Accurate Statements
Grapefruit juice interacts with Lipitor by inhibiting CYP3A4 and can increase plasma concentrations of atorvastatin.
Label 7.2: 'Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin...'
Grapefruit juice can increase risk of muscle damage with Lipitor (muscle pain/weakness/fatigue).
Label 5.1: 'Atorvastatin... occasionally causes myopathy… The concomitant use of higher doses of atorvastatin with certain drugs such as… strong CYP3A4 inhibitors… increases the risk of myopathy/rhabdomyolysis…' plus general muscle adverse reaction context.
Patients should avoid consuming grapefruit juice or excessive grapefruit juice consumption while taking Lipitor to minimize risks.
Label 7.2: grapefruit components 'inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day)'.
Unsupported Statements
Grapefruit juice inhibits the enzyme responsible for breaking down Lipitor in the liver, leading to higher levels of the medication in the bloodstream.
Supported that grapefruit components inhibit CYP3A4 and can increase plasma concentrations (7.2), but the provided excerpts do not state 'in the liver' or 'the enzyme responsible for breaking down Lipitor' in that exact causal phrasing.
Grapefruit juice can increase the risk of kidney damage, including kidney failure, when taking Lipitor.
Label 5.1 mentions rhabdomyolysis with 'acute renal failure secondary to myoglobinuria' (kidney involvement), but the provided excerpts do not specifically connect grapefruit juice to kidney failure risk.
Grapefruit juice can interact with other medications, including blood thinners, diabetes medications, and certain antibiotics.
The provided label excerpts only specifically address grapefruit juice interaction with atorvastatin (7.2) and other specific CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, protease inhibitors, cyclosporine). No provided excerpt supports the specific listed medication classes as being grapefruit-related interactions.
The risk of muscle damage and liver damage increased significantly when Lipitor was taken with grapefruit juice (as described in the provided text).
The provided label excerpt (7.2) supports increased plasma concentrations, but the supplied label text does not provide an 'increased significantly' quantitative comparison for grapefruit co-administration or explicitly separate muscle vs liver damage increases specifically due to grapefruit.
The interaction between grapefruit juice and Lipitor can occur within 30 minutes to 1 hour after consumption.
No timing information for grapefruit interaction is present in the provided excerpts.
Avoid consuming any type of citrus juice while taking Lipitor (as stated in the provided text).
The label excerpt specifically mentions grapefruit juice components inhibiting CYP3A4 (7.2) and does not support 'any type of citrus juice'.
Taking Lipitor with other medications requires consulting a doctor or pharmacist (as stated in the provided text).
No such counseling statement appears in the supplied label excerpts.
Symptoms of muscle damage caused by Lipitor (including when combined with grapefruit juice) can include muscle pain, weakness, and fatigue.
The supplied label excerpts discuss myopathy/rhabdomyolysis risk (5.1) but do not list specific symptom triads (pain/weakness/fatigue) nor explicitly mention grapefruit combination symptomatology.
Elevated levels of Lipitor in the bloodstream can increase the risk of liver damage, including liver failure.
The provided excerpts discuss liver enzyme elevations and caution/contraindications (5.2) and grapefruit increasing plasma concentrations (7.2), but do not support a causal claim that increased atorvastatin plasma levels from grapefruit specifically increase risk of 'liver failure'.
Lipitor works by inhibiting the production of cholesterol in the liver.
The provided mechanism excerpt is an 'inhibitor of HMG-CoA reductase' (12.1), but the provided label excerpts do not explicitly phrase it as 'inhibiting the production of cholesterol in the liver' (even though cholesterol biosynthesis is implied by the enzyme target). The exact phrasing is not supported by the excerpt provided.
Lipitor lowers LDL cholesterol levels in the blood.
The label excerpt supports reducing LDL-C levels (1.2, and 1.1/clinical context), but the specific wording 'in the blood' is not a mismatch; however this statement is not directly tied to an excerpt about 'in the blood' in the supplied text. It is broadly supported by 'reduce... LDL-C' (1.2), but because the claim is not directly verifiable to 'in the blood' wording, it is treated as not fully supported rather than contradiction.
Contradictions
Low
AI Statement
Avoid consuming any type of citrus juice while taking Lipitor.
Label Reference
Label 7.2 mentions grapefruit juice specifically; supplied excerpts do not support extending to all citrus juices.
Important Omissions
The label excerpt for grapefruit includes a specificity threshold ('especially with excessive grapefruit juice consumption (>1.2 liters per day)') rather than a total ban on grapefruit.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements extend beyond the provided label excerpts (kidney failure connection to grapefruit; 'any citrus juice'; interaction timing; broad medication class interactions), which could lead to overgeneralized avoidance or misunderstanding of risk specifics. Core grapefruit-CYP3A4 plasma concentration concept is supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple grapefruit-related and adverse-effect scope/timing claims are not supported by the provided label excerpts (e.g., all citrus juice, 30–60 minute timing, kidney failure from grapefruit, and specific symptom lists).
Suggested Improvement
Limit grapefruit juice claims to what the label excerpt supports: grapefruit juice components inhibit CYP3A4 and can increase atorvastatin plasma concentrations, especially with excessive intake (>1.2 L/day). Avoid adding unsupported timing, broader citrus categories, renal failure specificity, or specific symptom triads unless present in the provided prescribing information.